Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Beate Bittner. (2023) Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework. Expert Opinion on Drug Delivery 20:4, pages 457-470.
Read now
Read now
Advait V Badkar, Rajesh B Gandhi, Shawn P Davis & Michael J LaBarre. (2021) Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements. Drug Design, Development and Therapy 15, pages 159-170.
Read now
Read now
Marco Boeri, Boglarka Szegvari, Brett Hauber, Brennan Mange, Irina Mountian, Michael Schiff & Nikolaos Maniadakis. (2019) From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices. Patient Preference and Adherence 13, pages 1093-1110.
Read now
Read now
Bart J. F. van den Bemt, Lynda Gettings, Barbara Domańska, Richard Bruggraber, Irina Mountian & Lars E. Kristensen. (2019) A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Delivery 26:1, pages 384-392.
Read now
Read now
Andreas E. Schneider & Jakob Lange. (2018) Pen devices for self-injection: contrasting measured injection force with users’ perceived ease of injection. Expert Opinion on Drug Delivery 15:2, pages 115-125.
Read now
Read now
Articles from other publishers (7)
Yan Ji, Claudio Calonder, Tiina Kirsilä, Alis Burciu, Matjaz Tisu, Yolandi Joubert, Nathalie Laurent, Eva Hua, Manmath Patekar, Anton Drollmann & Ralph Woessner. (2023) Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System. Pharmaceutics 15:9, pages 2266.
Crossref
Crossref
Beate Bittner. (2023) Customer-centric product presentations for monoclonal antibodies. AAPS Open 9:1.
Crossref
Crossref
Roy M. Fleischmann, Amy E. Bock, Wuyan Zhang, Charles M. Godfrey, Ivana Vranic, Carol Cronenberger & Eva Dokoupilová. (2022) Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology and Therapy 9:3, pages 839-850.
Crossref
Crossref
Erinc Sahin & Smeet Deshmukh. (2019) Challenges and Considerations in Development and Manufacturing of High Concentration Biologics Drug Products. Journal of Pharmaceutical Innovation 15:2, pages 255-267.
Crossref
Crossref
Betty Hsiao & Liana Fraenkel. (2019) Patient preferences for rheumatoid arthritis treatment. Current Opinion in Rheumatology 31:3, pages 256-263.
Crossref
Crossref
Martin Schipperus, Georgia Kaiafa, Louise Taylor, Sally Wetten, Georg Kreuzbauer, Andy Boshier & Anouchka Seesaghur. (2018) Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study. Drug Safety 42:1, pages 77-83.
Crossref
Crossref
Barbara Domańska, Oliver Stumpp, Steven Poon, Serkan Oray, Irina Mountian & Clovis Pichon. (2017) Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies. Advances in Therapy 35:1, pages 100-115.
Crossref
Crossref